Oslo Universitetssykehus Aker
Oslo, Norway
2 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Diabetes Mellitus, Type 1
Eli Lilly and Company150 enrolled108 locationsNCT07222137
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Diabetes Mellitus, Type 1
Eli Lilly and Company300 enrolled129 locationsNCT07222332